Stockscreener 앱 받기
2.43
0.41%
0.01
시장 영업 전:
2.40
-0.03
-1.23%
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
How to build a custom watchlist for Caribou Biosciences Inc.Price Action & Stepwise Entry/Exit Trade Alerts - newser.com
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
Caribou Bio leaps on early data for vispa-cel - The Pharma Letter
CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus
Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener
Comparing Caribou Biosciences Inc. in custom built stock radarsWall Street Watch & Verified Momentum Stock Ideas - newser.com
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com
Caribou Says Potential Non-Hodgkin Lymphoma Therapy Shows High Overall Response; Shares Rise Pre-Bell - MarketScreener
Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
What machine learning models say about Caribou Biosciences Inc.July 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthDay Trade & Precise Buy Zone Tips - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedSwing Trade & High Conviction Investment Ideas - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Is Caribou Biosciences Inc. stock a contrarian buyEarnings Beat & High Accuracy Buy Signal Tips - newser.com
Caribou Biosciences Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Intraday pattern recognizer results for Caribou Biosciences Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
0.64%
0.35%
자본화:
|
볼륨(24시간):